Antiepileptic drug withdrawal and seizure severity in the epilepsy monitoring unit
Duy PQ, Krauss GL, Crone NE, Ma M, Johnson EL. Antiepileptic drug withdrawal and seizure severity in the epilepsy monitoring unit. Epilepsy & Behavior 2020, 109: 107128. PMID: 32417383, DOI: 10.1016/j.yebeh.2020.107128.Peer-Reviewed Original ResearchConceptsEpilepsy monitoring unitBilateral tonic-clonic seizuresSevere seizure typeTonic-clonic seizuresFocal seizuresSeizure typesAED doseLorazepam administrationAntiepileptic drug reductionAntiepileptic drug withdrawalDrug withdrawal ratesReceiver-operating characteristic curveRisk of complicationsAED dosageAED withdrawalEMU stayConsecutive patientsSeizure clustersAED reductionDrug withdrawalSeizure severityPresurgical patientsDrug reductionSeizuresEffective dosePreclinical insights into therapeutic targeting of KCC2 for disorders of neuronal hyperexcitability
Duy PQ, He M, He Z, Kahle KT. Preclinical insights into therapeutic targeting of KCC2 for disorders of neuronal hyperexcitability. Expert Opinion On Therapeutic Targets 2020, 24: 629-637. PMID: 32336175, PMCID: PMC8104019, DOI: 10.1080/14728222.2020.1762174.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAnticonvulsantsDrug DiscoveryDrug Evaluation, PreclinicalEpilepsyHumansMolecular Targeted TherapyNeuronsSymportersConceptsNeuronal hyperexcitabilityKCC2 functionSynaptic inhibitionKCC2 activityPreclinical insightsRole of KCC2Treatment of epilepsyCommon neurological disorderNovel therapeutic strategiesPotential adverse effectsDrug targetsKCC2 dysfunctionSeizure reductionUnprovoked seizuresIntractable epilepsySeizure activityEpilepsy therapyCotransporter KCC2Clinical urgencyPreclinical proofTherapeutic benefitTherapeutic strategiesNew drug targetsTherapeutic targetingKCC2